Physician profile
Frank Lee
NPI 1609197532
$12,422.42
in general payments reported to CMS, 2019-2025
27 companies · $2,016 in 2025
The $2,016 reported for 2025 was more than what 88% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $789 · 2020: $1,204 · 2021: $1,904 · 2022: $1,268 · 2023: $2,438 · 2024: $2,804 · 2025: $2,016.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,629 · Travel and Lodging: $629.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,628.98 |
| Travel and Lodging | $629.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $2,743.00 | 2021-2025 | Hydrus Microstent, Tryptyr, Clareon |
| Bausch & Lomb Americas INC. | $1,777.78 | 2023-2025 | Stellaris Elite, Teneo, Envista Aspire Iol |
| Ivantis, INC | $1,717.95 | 2020-2021 | |
| Glaukos Corporation | $977.84 | 2019-2025 | Idose, Radius, Idosetr |
| Sight Sciences, INC. | $947.45 | 2020-2024 | Omni Surgical System |
| Rxsight INC | $655.83 | 2023-2025 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Rxsight Contact Lens |
| Sun Pharmaceutical Industries INC. | $406.79 | 2019-2023 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $329.00 | 2019-2020 | |
| Dompe US, INC. | $303.40 | 2019 | |
| Oyster Point Pharma, INC. | $302.53 | 2023 | Tyrvaya |
| Biotissue Holdings INC. | $284.36 | 2022-2023 | |
| Abbvie INC. | $243.73 | 2023-2025 | |
| Johnson & Johnson Surgical Vision, INC. | $232.13 | 2019-2021 | |
| Apellis Pharmaceuticals, INC. | $202.02 | 2022-2023 | Syfovre |
| Ani Pharmaceuticals, INC. | $168.55 | 2023-2025 | Purified Cortrophin Gel |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $164.78 | 2019-2021 | |
| Harrow Eye, LLC | $150.07 | 2025 | Vevye |
| Novartis Pharmaceuticals Corporation | $118.85 | 2019 | |
| Astellas Pharma US INC | $118.51 | 2023 | |
| Tarsus Pharmaceuticals, INC. | $116.82 | 2024 | |
| Eyevance Pharmaceuticals LLC | $114.87 | 2019-2022 | |
| Kala Pharmaceuticals, INC. | $111.07 | 2021 | |
| Thea Pharma INC. | $108.17 | 2025 | Iyuzeh |
| Depuy Synthes Sales INC. | $63.33 | 2019 | |
| Boston Scientific Corporation | $24.25 | 2023 | |
| Ocular Therapeutix, INC. | $20.38 | 2025 | Dextenza |
| Horizon Therapeutics Plc | $18.96 | 2023 | Tepezza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frank Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.